Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB01819"

Predicate	Value (sorted: default)
rdfs:label	"Phosphoenolpyruvate"
rdf:type	drugbank:drugs
drugbank:description	" 138-08-9 experimental Naotaka Hamasaki, Hirotaka Kawamura, Norio Ohtsu, Ichiro Nakakoshi, Kikuo Ataka, Kiyosi Oomori, Masahiko Kouno, "Process for preparing monosodium phosphoenolpyruvate." U.S. Patent US4874882, issued October, 1984. This compound belongs to the organophosphate esters. These are organic compounds containing phosphoric acid ester functional group. Organophosphate Esters Organic Compounds Organophosphorus Compounds Organic Phosphoric Acids and Derivatives Organophosphate Esters Organic Phosphoric Acids Enones Polyamines Enolates Carboxylic Acids enone enolate polyamine carboxylic acid carboxylic acid derivative logP -1.2 ALOGPS logS -1.1 ALOGPS Water Solubility 1.32e+01 g/l ALOGPS logP -0.64 ChemAxon IUPAC Name 2-(phosphonooxy)prop-2-enoic acid ChemAxon Traditional IUPAC Name phosphoenolpyruvate ChemAxon Molecular Weight 168.042 ChemAxon Monoisotopic Weight 167.982374404 ChemAxon SMILES OC(=O)C(=C)OP(O)(O)=O ChemAxon Molecular Formula C3H5O6P ChemAxon InChI InChI=1S/C3H5O6P/c1-2(3(4)5)9-10(6,7)8/h1H2,(H,4,5)(H2,6,7,8) ChemAxon InChIKey InChIKey=DTBNBXWJWCWCIK-UHFFFAOYSA-N ChemAxon Polar Surface Area (PSA) 104.06 ChemAxon Refractivity 30.13 ChemAxon Polarizability 11.57 ChemAxon Rotatable Bond Count 3 ChemAxon H Bond Acceptor Count 5 ChemAxon H Bond Donor Count 3 ChemAxon pKa (strongest acidic) 0.76 ChemAxon Physiological Charge -3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five true ChemAxon ChEBI 26055 PubChem Compound 1005 PubChem Substance 46506098 KEGG Compound C00074 ChemSpider 980 PDB PEP Wikipedia Phosphoenolpyruvate SMP00560 Phosphoenolpyruvate carboxykinase deficiency 1 (PEPCK1) DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00562 Fructose-1,6-diphosphatase deficiency DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00374 Glycogen Storage Disease Type 1A (GSD1A) or Von Gierke Disease DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00240 Salla Disease/Infantile Sialic Acid Storage Disease DB00119 Pyruvic acid DB00130 L-Glutamine DB00141 N-Acetyl-D-glucosamine DB00142 L-Glutamic Acid DB01296 Glucosamine DB01819 Phosphoenolpyruvate DB02431 Cytidine-5'-Triphosphate DB03166 Acetic acid DB03435 Uridine-5'-Diphosphate Q13231 P06865 Q9UJ70 Q9Y303 Q96EK6 P46926 Q06210 O95394 Q16222 P51606 Q9Y223 P19367 Q9NR45 Q9BXD5 Q8TBE9 Q8NFW8 Q9NRA2 SMP00045 Amino Sugar Metabolism DB00119 Pyruvic acid DB00130 L-Glutamine DB00141 N-Acetyl-D-glucosamine DB00142 L-Glutamic Acid DB01296 Glucosamine DB01819 Phosphoenolpyruvate DB02431 Cytidine-5'-Triphosphate DB03166 Acetic acid DB03435 Uridine-5'-Diphosphate Q13231 P06865 Q9UJ70 Q9Y303 Q96EK6 P46926 Q06210 O95394 Q16222 P51606 Q9Y223 P19367 Q9NR45 Q9BXD5 Q8TBE9 Q8NFW8 Q9NRA2 SMP00534 G(M2)-Gangliosidosis: Variant B, Tay-sachs disease DB00119 Pyruvic acid DB00130 L-Glutamine DB00141 N-Acetyl-D-glucosamine DB00142 L-Glutamic Acid DB01296 Glucosamine DB01819 Phosphoenolpyruvate DB02431 Cytidine-5'-Triphosphate DB03166 Acetic acid DB03435 Uridine-5'-Diphosphate Q13231 P06865 Q9UJ70 Q9Y303 Q96EK6 P46926 Q06210 O95394 Q16222 P51606 Q9Y223 P19367 Q9NR45 Q9BXD5 Q8TBE9 Q8NFW8 Q9NRA2 SMP00572 Fanconi-bickel syndrome DB00119 Pyruvic acid DB01345 Potassium DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P52789 Q96C23 P06744 P08237 P04075 P60174 P35575 P04406 P07738 Q8TE04 P18669 P15259 P06733 P30613 SMP00212 Pyruvate Dehydrogenase Complex Deficiency DB00119 Pyruvic acid DB00121 Biotin DB00143 Glutathione DB01345 Potassium DB01593 Zinc DB01819 Phosphoenolpyruvate DB01839 1,2-Propanediol DB03066 D-Lactic Acid DB03166 Acetic acid DB04524 Malonyl-Coenzyme A P11498 Q6ZMR3 P30613 P35558 P40925 P23368 Q86WU2 Q16775 Q04760 Q9UBQ7 P15121 P48163 P09622 P10515 Q13085 P24752 Q8WYK0 P07311 P05091 Q9NR19 P08559 P11177 SMP00334 Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency) DB00119 Pyruvic acid DB00121 Biotin DB00143 Glutathione DB01345 Potassium DB01593 Zinc DB01819 Phosphoenolpyruvate DB01839 1,2-Propanediol DB03066 D-Lactic Acid DB03166 Acetic acid DB04524 Malonyl-Coenzyme A P11498 Q6ZMR3 P30613 P35558 P40925 P23368 Q86WU2 Q16775 Q04760 Q9UBQ7 P15121 P48163 P09622 P10515 Q13085 P24752 Q8WYK0 P07311 P05091 Q9NR19 P08559 P11177 SMP00559 Pyruvate kinase deficiency DB00119 Pyruvic acid DB00121 Biotin DB00143 Glutathione DB01345 Potassium DB01593 Zinc DB01819 Phosphoenolpyruvate DB01839 1,2-Propanediol DB03066 D-Lactic Acid DB03166 Acetic acid DB04524 Malonyl-Coenzyme A P11498 Q6ZMR3 P30613 P35558 P40925 P23368 Q86WU2 Q16775 Q04760 Q9UBQ7 P15121 P48163 P09622 P10515 Q13085 P24752 Q8WYK0 P07311 P05091 Q9NR19 P08559 P11177 SMP00390 Tay-Sachs Disease DB00119 Pyruvic acid DB00130 L-Glutamine DB00141 N-Acetyl-D-glucosamine DB00142 L-Glutamic Acid DB01296 Glucosamine DB01819 Phosphoenolpyruvate DB02431 Cytidine-5'-Triphosphate DB03166 Acetic acid DB03435 Uridine-5'-Diphosphate Q13231 P06865 Q9UJ70 Q9Y303 Q96EK6 P46926 Q06210 O95394 Q16222 P51606 Q9Y223 P19367 Q9NR45 Q9BXD5 Q8TBE9 Q8NFW8 Q9NRA2 SMP00531 Glycogenosis, Type VII. Tarui disease DB00119 Pyruvic acid DB01345 Potassium DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P52789 Q96C23 P06744 P08237 P04075 P60174 P35575 P04406 P07738 Q8TE04 P18669 P15259 P06733 P30613 SMP00581 Glycogenosis, Type IA. Von gierke disease DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00654 Warburg Effect DB00119 Pyruvic acid DB00121 Biotin DB00130 L-Glutamine DB00139 Succinic acid DB00142 L-Glutamic Acid DB01345 Potassium DB01677 Fumarate DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04272 Citric Acid DB04326 1,3-Dihydroxyacetonephosphate P11168 P52789 P06744 P17858 P05062 P04406 P00558 P15259 P06733 P30613 Q9Y5U8 P11498 P08559 P11177 P10515 P09622 O75390 Q6ZMR3 P53985 Q99798 P50213 O43837 P51553 Q02218 P36957 P53597 Q96I99 P31040 P21912 Q99643 O14521 P07954 P40925 P00367 Q9UI32 Q15758 P37837 P29401 P49247 O95336 P11413 P52209 Q6LAP8 P21399 O75874 P14618 SMP00216 Sialuria or French Type Sialuria DB00119 Pyruvic acid DB00130 L-Glutamine DB00141 N-Acetyl-D-glucosamine DB00142 L-Glutamic Acid DB01296 Glucosamine DB01819 Phosphoenolpyruvate DB02431 Cytidine-5'-Triphosphate DB03166 Acetic acid DB03435 Uridine-5'-Diphosphate Q13231 P06865 Q9UJ70 Q9Y303 Q96EK6 P46926 Q06210 O95394 Q16222 P51606 Q9Y223 P19367 Q9NR45 Q9BXD5 Q8TBE9 Q8NFW8 Q9NRA2 SMP00128 Gluconeogenesis DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00574 Glycogenosis, Type IC DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00573 Glycogenosis, Type IB DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00040 Glycolysis DB00119 Pyruvic acid DB01345 Potassium DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P52789 Q96C23 P06744 P08237 P04075 P60174 P35575 P04406 P07738 Q8TE04 P18669 P15259 P06733 P30613 SMP00558 Primary hyperoxaluria II, PH2 DB00119 Pyruvic acid DB00121 Biotin DB00143 Glutathione DB01345 Potassium DB01593 Zinc DB01819 Phosphoenolpyruvate DB01839 1,2-Propanediol DB03066 D-Lactic Acid DB03166 Acetic acid DB04524 Malonyl-Coenzyme A P11498 Q6ZMR3 P30613 P35558 P40925 P23368 Q86WU2 Q16775 Q04760 Q9UBQ7 P15121 P48163 P09622 P10515 Q13085 P24752 Q8WYK0 P07311 P05091 Q9NR19 P08559 P11177 SMP00563 Triosephosphate isomerase DB00119 Pyruvic acid DB00121 Biotin DB01709 2-Phosphoglyceric Acid DB01819 Phosphoenolpyruvate DB02263 Glyceraldehyde-3-Phosphate DB04326 1,3-Dihydroxyacetonephosphate P11168 P35575 O43826 P36871 P06744 P52789 Q96C23 P09467 P04075 P60174 P04406 Q8TE04 P15259 P06733 P07738 P18669 P35558 P40926 Q02978 P11498 Q9Y5U8 Q6ZMR3 SMP00217 Sjogren Larsson Syndrome DB00119 Pyruvic acid DB00130 L-Glutamine DB00141 N-Acetyl-D-glucosamine DB00142 L-Glutamic Acid DB01296 Glucosamine DB01819 Phosphoenolpyruvate DB02431 Cytidine-5'-Triphosphate DB03166 Acetic acid DB03435 Uridine-5'-Diphosphate Q13231 P06865 Q9UJ70 Q9Y303 Q96EK6 P46926 Q06210 O95394 Q16222 P51606 Q9Y223 P19367 Q9NR45 Q9BXD5 Q8TBE9 Q8NFW8 Q9NRA2 SMP00196 Leigh Syndrome DB00119 Pyruvic acid DB00121 Biotin DB00143 Glutathione DB01345 Potassium DB01593 Zinc DB01819 Phosphoenolpyruvate DB01839 1,2-Propanediol DB03066 D-Lactic Acid DB03166 Acetic acid DB04524 Malonyl-Coenzyme A P11498 Q6ZMR3 P30613 P35558 P40925 P23368 Q86WU2 Q16775 Q04760 Q9UBQ7 P15121 P48163 P09622 P10515 Q13085 P24752 Q8WYK0 P07311 P05091 Q9NR19 P08559 P11177 SMP00060 Pyruvate Metabolism DB00119 Pyruvic acid DB00121 Biotin DB00143 Glutathione DB01345 Potassium DB01593 Zinc DB01819 Phosphoenolpyruvate DB01839 1,2-Propanediol DB03066 D-Lactic Acid DB03166 Acetic acid DB04524 Malonyl-Coenzyme A P11498 Q6ZMR3 P30613 P35558 P40925 P23368 Q86WU2 Q16775 Q04760 Q9UBQ7 P15121 P48163 P09622 P10515 Q13085 P24752 Q8WYK0 P07311 P05091 Q9NR19 P08559 P11177 BE0002004 Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive Escherichia coli (strain K12) # Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284 # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423 unknown Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive Amino acid transport and metabolism Stereospecific condensation of phosphoenolpyruvate (PEP) and D-erythrose-4-phosphate (E4P) giving rise to 3-deoxy-D- arabino-heptulosonate-7-phosphate (DAHP) aroG None 6.58 38010.0 Escherichia coli (strain K12) GenBank Gene Database J01591 GenBank Protein Database 145368 UniProtKB P0AB91 UniProt Accession AROG_ECOLI 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase DAHP synthetase EC 2.5.1.54 Phospho-2-keto-3-deoxyheptonate aldolase >Phospho-2-dehydro-3-deoxyheptonate aldolase, Phe-sensitive MNYQNDDLRIKEIKELLPPVALLEKFPATENAANTVAHARKAIHKILKGNDDRLLVVIGP CSIHDPVAAKEYATRLLALREELKDELEIVMRVYFEKPRTTVGWKGLINDPHMDNSFQIN DGLRIARKLLLDINDSGLPAAGEFLDMITPQYLADLMSWGAIGARTTESQVHRELASGLS CPVGFKNGTDGTIKVAIDAINAAGAPHCFLSVTKWGHSAIVNTSGNGDCHIILRGGKEPN YSAKHVAEVKEGLNKAGLPAQVMIDFSHANSSKQFKKQMDVCADVCQQIAGGEKAIIGVM VESHLVEGNQSLESGEPLAYGKSITDACIGWEDTDALLRQLANAVKARRG >1053 bp ATGAATTATCAGAACGACGATTTACGCATCAAAGAAATCAAAGAGTTACTTCCTCCTGTC GCATTGCTGGAAAAATTCCCCGCTACTGAAAATGCCGCGAATACGGTTGCCCATGCCCGA AAAGCGATCCATAAGATCCTGAAAGGTAATGATGATCGCCTGTTGGTTGTGATTGGCCCA TGCTCAATTCATGATCCTGTCGCGGCAAAAGAGTATGCCACTCGCTTGCTGGCGCTGCGT GAAGAGCTGAAAGATGAGCTGGAAATCGTAATGCGCGTCTATTTTGAAAAGCCGCGTACC ACGGTGGGCTGGAAAGGGCTGATTAACGATCCGCATATGGATAATAGCTTCCAGATCAAC GACGGTCTGCGTATAGCCCGTAAATTGCTGCTTGATATTAACGACAGCGGTCTGCCAGCG GCAGGTGAGTTTCTCGATATGATCACCCCACAATATCTCGCTGACCTGATGAGCTGGGGC GCAATTGGCGCACGTACCACCGAATCGCAGGTGCACCGCGAACTGGCATCAGGGCTTTCT TGTCCGGTCGGCTTCAAAAATGGCACCGACGGTACGATTAAAGTGGCTATCGATGCCATT AATGCCGCCGGTGCGCCGCACTGCTTCCTGTCCGTAACGAAATGGGGGCATTCGGCGATT GTGAATACCAGCGGTAACGGCGATTGCCATATCATTCTGCGCGGCGGTAAAGAGCCTAAC TACAGCGCGAAGCACGTTGCTGAAGTGAAAGAAGGGCTGAACAAAGCAGGCCTGCCAGCA CAGGTGATGATCGATTTCAGCCATGCTAACTCGTCCAAACAATTCAAAAAGCAGATGGAT GTTTGTGCTGACGTTTGCCAGCAGATTGCCGGTGGCGAAAAGGCCATTATTGGCGTGATG GTGGAAAGCCATCTGGTGGAAGGCAATCAGAGCCTCGAGAGCGGGGAGCCGCTGGCCTAC GGTAAGAGCATCACCGATGCCTGCATCGGCTGGGAAGATACCGATGCTCTGTTACGTCAA CTGGCGAATGCAGTAAAAGCGCGTCGCGGGTAA PF00793 DAHP_synth_1 function transferase activity function transferase activity, transferring alkyl or aryl (other than methyl) groups function 3-deoxy-7-phosphoheptulonate synthase activity function catalytic activity process amino acid and derivative metabolism process biosynthesis process amino acid biosynthesis process aromatic amino acid family biosynthesis process physiological process process metabolism process cellular metabolism process amino acid metabolism BE0001394 2-dehydro-3-deoxyphosphooctonate aldolase Shigella flexneri # Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284 # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423 unknown 2-dehydro-3-deoxyphosphooctonate aldolase Cell wall/membrane/envelope biogenesis Phosphoenolpyruvate + D-arabinose 5-phosphate + H(2)O = 2-dehydro-3-deoxy-D-octonate 8-phosphate + phosphate kdsA Cytoplasm None 6.79 30833.0 Shigella flexneri GenBank Gene Database AE005674 GenBank Protein Database 24051519 UniProtKB P0A716 UniProt Accession KDSA_SHIFL 3-deoxy-D-manno-octulosonic acid 8- phosphate synthetase EC 2.5.1.55 KDO 8-P synthase KDO-8-phosphate synthetase KDOPS Phospho-2- dehydro-3-deoxyoctonate aldolase >2-dehydro-3-deoxyphosphooctonate aldolase MKQKVVSIGDINVANDLPFVLFGGMNVLESRDLAMRICEHYVTVTQKLGIPYVFKASFDK ANRSSIHSYRGPGLEEGMKIFQELKQTFGVKIITDVHEPSQAQPVADVVDVIQLPAFLAR QTDLVEAMAKTGAVINVKKPQFVSPGQMGNIVDKFKEGGNEKVILCDRGANFGYDNLVVD MLGFSIMKKVSGNSPVIFDVTHALQCRDPFGAASGGRRAQVAELARAGMAVGLAGLFIEA HPDPEHAKCDGPSALPLAKLEPFLKQMKAIDDLVKGFEELDTSK >855 bp ATGAAACAAAAAGTGGTTAGCATTGGCGACATCAACGTAGCAAATGACCTGCCGTTCGTA CTGTTTGGCGGTATGAACGTGCTGGAATCTCGCGATCTGGCGATGCGCATTTGCGAGCAC TACGTAACTGTGACCCAGAAACTGGGTATCCCTTACGTGTTCAAAGCCTCTTTTGACAAA GCCAACCGCTCCTCCATCCACTCTTATCGTGGACCGGGCCTGGAAGAAGGGATGAAAATC TTCCAGGAGTTGAAGCAGACTTTTGGCGTGAAAATTATCACCGACGTTCACGAACCAAGT CAGGCACAGCCCGTTGCTGATGTCGTGGATGTGATTCAGTTGCCGGCGTTTCTTGCTCGC CAGACTGACCTGGTTGAAGCCATGGCGAAAACCGGTGCGGTAATTAACGTCAAGAAACCA CAGTTTGTCAGCCCGGGACAGATGGGTAATATCGTTGATAAATTCAAAGAAGGCGGCAAC GAAAAAGTGATTCTTTGCGATCGTGGTGCTAACTTCGGCTATGACAACCTGGTTGTCGAT ATGCTGGGCTTCAGCATTATGAAGAAAGTGTCTGGTAACTCGCCGGTGATTTTCGACGTG ACCCACGCACTGCAATGCCGCGATCCGTTTGGCGCAGCTTCCGGTGGTCGTCGTGCTCAG GTGGCTGAGCTGGCACGAGCCGGTATGGCGGTAGGTCTGGCGGGGCTGTTTATTGAAGCG CATCCGGATCCGGAACATGCGAAATGTGATGGTCCATCCGCGCTGCCGCTGGCTAAACTG GAACCGTTCCTCAAGCAGATGAAAGCGATTGATGATCTGGTGAAAGGTTTCGAAGAACTG GATACCAGCAAGTAA PF00793 DAHP_synth_1 component intracellular component cytoplasm component cell function transferase activity, transferring alkyl or aryl (other than methyl) groups function 3-deoxy-8-phosphooctulonate synthase activity function catalytic activity function transferase activity process physiological process process metabolism process biosynthesis BE0004460 Beta-enolase Human # Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284 # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423 # Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10592235 unknown Beta-enolase ENO3 Human UniProtKB P13929 UniProt Accession ENOB_HUMAN BE0002562 Capsule biosynthesis protein Neisseria meningitidis unknown Capsule biosynthesis protein Cell wall/membrane/envelope biogenesis synC None 5.18 38348.0 Neisseria meningitidis GenBank Gene Database U40740 UniProtKB Q57265 UniProt Accession Q57265_NEIME SiaC >Capsule biosynthesis protein MQNNNEFKIGNRSVGYNHEPLIICEIGINHEGSLKTAFEMVDAAYNAGAEVVKHQTHIVE DEMSDEAKQVIPGNADVSIYEIMERCALNEEDEIKLKEYVESKGMIFISTPFSRAAALRL QRMDIPAYKIGSGECNNYPLIKLVASFGKPIILSTGMNSIESIKKSVEIIREAGVPYALL HCTNIYPTPYEDVRLGGMNDLSEAFPDAIIGLSDHTLDNYACLGAVALGGSILERHFTDR MDRPGPDIVCSMNPDTFKELKQGAHALKLARGGKKDTIIAGEKPTKDFAFASVVADKDIK KGELLSGDNLWVKRPGNGDFSVNEYETLFGKVAACNIRKGAQIKKTDIE >1050 bp ATGCAAAACAACAACGAATTTAAAATTGGTAATCGTTCAGTAGGTTACAACCACGAACCA TTGATTATCTGTGAAATCGGCATCAATCATGAAGGCTCTTTAAAAACAGCTTTTGAAATG GTTGATGCTGCCTATAATGCAGGCGCTGAAGTTGTTAAACATCAAACACACATCGTTGAA GACGAAATGTCTGATGAGGCCAAACAAGTCATTCCAGGCAATGCAGATGTCTCTATTTAT GAAATTATGGAACGTTGCGCCCTGAATGAAGAAGATGAGATTAAATTAAAAGAATACGTA GAGAGTAAGGGTATGATTTTTATCAGTACTCCTTTCTCTCGTGCAGCTGCTTTACGATTA CAACGTATGGATATTCCAGCATATAAAATCGGCTCTGGCGAATGTAATAACTACCCATTA ATTAAACTGGTGGCCTCTTTTGGTAAGCCTATTATTCTCTCTACCGGCATGAATTCTATT GAAAGCATCAAAAAGTCGGTAGAAATTATTCGAGAAGCAGGGGTACCTTATGCTTTGCTT CACTGTACCAACATCTACCCAACCCCTTACGAAGATGTTCGATTGGGTGGTATGAACGAT TTATCTGAAGCCTTTCCAGACGCAATCATTGGCCTGTCTGACCATACCTTAGATAACTAT GCTTGCTTAGGAGCAGTAGCTTTAGGCGGTTCGATTTTAGAGCGTCACTTTACTGACCGC ATGGATCGCCCAGGTCCGGATATTGTATGCTCTATGAATCCGGATACTTTTAAAGAGCTC AAGCAAGGCGCTCATGCTTTAAAATTGGCACGCGGCGGCAAAAAAGACACGATTATCGCG GGAGAAAAGCCAACTAAAGATTTCGCCTTTGCATCTGTCGTAGCAGATAAAGACATTAAA AAAGGAGAACTGTTGTCCGGAGATAACCTATGGGTTAAACGCCCAGGCAATGGAGACTTC AGCGTCAACGAATATGAAACATTATTTGGTAAGGTCGCTGCTTGCAATATTCGCAAAGGT GCTCAAATCAAAAAAACTGATATTGAATAA PF03102 NeuB BE0000906 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Human # Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284 # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423 unknown Phosphoenolpyruvate carboxykinase, cytosolic [GTP] Energy production and conversion GTP + oxaloacetate = GDP + phosphoenolpyruvate + CO(2) PCK1 20q13.31 Cytoplasm None 6.05 69195.0 Human HUGO Gene Nomenclature Committee (HGNC) HGNC:8724 GenAtlas PCK1 GeneCards PCK1 GenBank Gene Database L05144 GenBank Protein Database 189945 UniProtKB P35558 UniProt Accession PCKGC_HUMAN EC 4.1.1.32 PEPCK-C Phosphoenolpyruvate carboxylase >Phosphoenolpyruvate carboxykinase, cytosolic [GTP] MPPQLQNGLNLSAKVVQGSLDSLPQAVREFLENNAELCQPDHIHICDGSEEENGRLLGQM EEEGILRRLKKYDNCWLALTDPRDVARIESKTVIVTQEQRDTVPIPKTGLSQLGRWMSEE DFEKAFNARFPGCMKGRTMYVIPFSMGPLGSPLSKIGIELTDSPYVVASMRIMTRMGTPV LEAVGDGEFVKCLHSVGCPLPLQKPLVNNWPCNPELTLIAHLPDRREIISFGSGYGGNSL LGKKCFALRMASRLAKEEGWLAEHMLILGITNPEGEKKYLAAAFPSACGKTNLAMMNPSL PGWKVECVGDDIAWMKFDAQGHLRAINPENGFFGVAPGTSVKTNPNAIKTIQKNTIFTNV AETSDGGVYWEGIDEPLASGVTITSWKNKEWSSEDGEPCAHPNSRFCTPASQCPIIDAAW ESPEGVPIEGIIFGGRRPAGVPLVYEALSWQHGVFVGAAMRSEATAAAEHKGKIIMHDPF AMRPFFGYNFGKYLAHWLSMAQHPAAKLPKIFHVNWFRKDKEGKFLWPGFGENSRVLEWM FNRIDGKASTKLTPIGYIPKEDALNLKGLGHINMMELFSISKEFWEKEVEDIEKYLEDQV NADLPCEIEREILALKQRISQM >1869 bp ATGCCTCCTCAGCTGCAAAACGGCCTGAACCTCTCGGCCAAAGTTGTCCAGGGAAGCCTG GACAGCCTGCCCCAGGCAGTGAGGGAGTTTCTCGAGAATAACGCTGAGCTGTGTCAGCCT GATCACATCCACATCTGTGACGGCTCTGAGGAGGAGAATGGGCGGCTTCTGGGCCAGATG GAGGAAGAGGGCATCCTCAGGCGGCTGAAGAAGTATGACAACTGCTGGTTGGCTCTCACT GACCCCAGGGATGTGGCCAGGATCGAAAGCAAGACGGTTATCGTCACCCAAGAGCAAAGA GACACAGTGCCCATCCCCAAAACAGGCCTCAGCCAGCTCGGTCGCTGGATGTCAGAGGAG GATTTTGAGAAAGCGTTCAATGCCAGGTTCCCAGGGTGCATGAAAGGTCGCACCATGTAC GTCATCCCATTCAGCATGGGGCCGCTGGGCTCACCTCTGTCGAAGATCGGCATCGAGCTG ACGGATTCGCCCTACGTGGTGGCCAGCATGCGGATCATGACGCGGATGGGCACGCCCGTC CTGGAAGCACTGGGCGATGGGGAGTTTGTCAAATGCCTCCATTCTGTGGGGTGCCCTCTG CCTTTACAAAAGCCTTTGGTCAACAACTGGCCCTGCAACCCGGAGCTGACGCTCATCGCC CACCTGCCTGACCGCAGAGAGATCATCTCCTTTGGCAGTGGGTACGGCGGGAACTCGCTG CTCGGGAAGAAGTGCTTTGCTCTCAGGATGGCCAGCCGGCTGGCAGAGGAGGAAGGGTGG CTGGCAGAGCACATGCTGATTCTGGGTATAACCAACCCTGAGGGTGAGAAGAAGTACCTG GCGGCCGCATTTCCCAGCGCCTGCGGGAAGACCAACCTGGCCATGATGAACCCCAGCCTC CCCGGGTGGAAGGTTGAGTGCGTCGGGGATGACATTGCCTGGATGAAGTTTGACGCACAA GGTCATTTAAGGGCCATCAACCCAGAAAATGGCTTTTTCGGTGTCGCTCCTGGGACTTCA GTGAAGACCAACCCCAATGCCATCAAGACCATCCAGAAGAACACAATCTTTACCAATGTG GCCGAGACCAGCGACGGGGGCGTTTACTGGGAAGGCATTGATGAGCCGCTAGCTTCAGGC GTCACCATCACGTCCTGGAAGAATAAGGAGTGGAGCTCAGAGGATGGGGAACCTTGTGCC CACCCCAACTCGAGGTTCTGCACCCCTGCCAGCCAGTGCCCCATCATTGATGCTGCCTGG GAGTCTCCGGAAGGTGTTCCCATTGAAGGCATTATCTTTGGAGGCCGTAGACCTGCTGGT GTCCCTCTAGTCTATGAAGCTCTCAGCTGGCAACATGGAGTCTTTGTGGGGGCGGCCATG AGATCAGAGGCCACAGCGGCTGCAGAACATAAAGGCAAAATCATCATGCATGACCCCTTT GCCATGCGGCCCTTCTTTGGCTACAACTTCGGCAAATACCTGGCCCACTGGCTTAGCATG GCCCAGCACCCAGCAGCCAAACTGCCCAAGATCTTCCATGTCAACTGGTTCCGGAAGGAC AAGGAAGGCAAATTCCTCTGGCCAGGCTTTGGAGAGAACTCCAGGGTGCTGGAGTGGATG TTCAACCGGATCGATGGAAAAGCCAGCACCAACGTCACGCCCATAGGCTACATCCCCAAG GAGGATGCCCTGAACCTGAAAGGCCTGGGGCACATCAACATGATGGAGCTTTTCAGCATC TCCAAGGAATTCTGGGACAAGGAGGTGGAAGACATCGAGAAGTATCTGGTGGATCAAGTC AATGCCGACCTCCCCTGTGAAATCGAGAGAGAGATCCTTGCCTTGAAGCAAAGAATAAGC CAGATGTAA PF00821 PEPCK function carbon-carbon lyase activity function phosphoenolpyruvate carboxykinase activity function carboxy-lyase activity function nucleotide binding function purine nucleotide binding function guanyl nucleotide binding function binding function GTP binding function catalytic activity function lyase activity process physiological process process alcohol metabolism process monosaccharide metabolism process metabolism process hexose metabolism process cellular metabolism process glucose metabolism process gluconeogenesis BE0001253 2-dehydro-3-deoxyphosphooctonate aldolase Aquifex aeolicus (strain VF5) # Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284 # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423 unknown 2-dehydro-3-deoxyphosphooctonate aldolase Cell wall/membrane/envelope biogenesis Phosphoenolpyruvate + D-arabinose 5-phosphate + H(2)O = 2-dehydro-3-deoxy-D-octonate 8-phosphate + phosphate kdsA Cytoplasm None 6.68 29735.0 Aquifex aeolicus (strain VF5) GenBank Gene Database AE000657 GenBank Protein Database 2982835 UniProtKB O66496 UniProt Accession KDSA_AQUAE 3-deoxy-D-manno-octulosonic acid 8- phosphate synthetase EC 2.5.1.55 KDO 8-P synthase KDO-8-phosphate synthetase KDOPS Phospho-2- dehydro-3-deoxyoctonate aldolase >2-dehydro-3-deoxyphosphooctonate aldolase MEKFLVIAGPCAIESEELLLKVGEEIKRLSEKFKEVEFVFKSSFDKANRSSIHSFRGHGL EYGVKALRKVKEEFGLKITTDIHESWQAEPVAEVADIIQIPAFLCRQTDLLLAAAKTGRA VNVKKGQFLAPWDTKNVVEKLKFGGAKEIYLTERGTTFGYNNLVVDFRSLPIMKQWAKVI YDATHSVQLPGGLGDKSGGMREFIFPLIRAAVAVGCDGVFMETHPEPEKALSDASTQLPL SQLEGIIEAILEIREVASKYYETIPVK >804 bp ATGGAAAAGTTTTTAGTGATAGCTGGACCCTGCGCGATAGAGAGCGAGGAACTTCTCCTA AAGGTAGGGGAGGAGATAAAGCGTTTATCGGAGAAGTTCAAAGAAGTTGAGTTCGTATTT AAGTCTTCCTTTGATAAAGCGAACCGCTCCTCAATACATTCCTTCAGGGGGCACGGTCTT GAATACGGGGTAAAGGCTCTGAGGAAGGTAAAGGAAGAGTTCGGACTGAAGATTACCACG GATATTCACGAGAGCTGGCAAGCTGAACCAGTTGCAGAAGTTGCGGACATAATCCAGATA CCTGCCTTTTTATGCAGGCAGACTGACCTCCTCCTTGCGGCTGCAAAAACGGGAAGGGCT GTAAACGTGAAGAAGGGTCAGTTTTTAGCCCCTTGGGACACGAAGAACGTGGTTGAAAAA TTAAAGTTCGGCGGTGCTAAGGAGATATACCTCACGGAGAGAGGAACTACCTTCGGATAC AACAACCTCGTTGTAGATTTCAGGAGCCTACCCATAATGAAACAGTGGGCAAAGGTTATA TACGACGCCACCCACAGCGTCCAGCTCCCCGGAGGTCTCGGGGACAAATCAGGAGGAATG AGGGAGTTTATATTCCCCTTAATCCGTGCTGCGGTTGCGGTAGGTTGTGACGGTGTGTTT ATGGAAACACACCCAGAACCAGAAAAGGCACTCTCGGACGCATCAACTCAGCTTCCCCTC TCCCAGCTGGAAGGGATAATAGAGGCTATCCTTGAGATAAGGGAAGTGGCTTCAAAGTAT TACGAAACAATTCCCGTTAAATGA PF00793 DAHP_synth_1 component cell component intracellular component cytoplasm function transferase activity function transferase activity, transferring alkyl or aryl (other than methyl) groups function 3-deoxy-8-phosphooctulonate synthase activity function catalytic activity process metabolism process biosynthesis process physiological process BE0001721 Phospho-2-dehydro-3-deoxyheptonate aldolase Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099) # Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17139284 # Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17016423 unknown Phospho-2-dehydro-3-deoxyheptonate aldolase Amino acid transport and metabolism Catalyzes the condensation of phosphoenolpyruvate (PEP) and D-erythrose-4-phosphate (E4P) giving rise to 3-deoxy-D- arabino-heptulosonate-7-phosphate (DAHP) aroF None 6.64 37379.0 Thermotoga maritima (strain ATCC 43589 / MSB8 / DSM 3109 / JCM 10099) GenBank Gene Database AE000512 GenBank Protein Database 4980844 UniProtKB Q9WYH8 UniProt Accession AROF_THEMA 3-deoxy-D-arabino- heptulosonate 7-phosphate synthase DAHP synthetase EC 2.5.1.54 Phospho-2- keto-3-deoxyheptonate aldolase >Phospho-2-dehydro-3-deoxyheptonate aldolase MIVVLKPGSTEEDIRKVVKLAESYNLKCHISKGQERTVIGIIGDDRYVVADKFESLDCVE SVVRVLKPYKLVSREFHPEDTVIDLGDVKIGNGYFTIIAGPCSVEGREMLMETAHFLSEL GVKVLRGGAYKPRTSPYSFQGLGEKGLEYLREAADKYGMYVVTEALGEDDLPKVAEYADI IQIGARNAQNFRLLSKAGSYNKPVLLKRGFMNTIEEFLLSAEYIANSGNTKIILCERGIR TFEKATRNTLDISAVPIIRKESHLPILVDPSHSGGRRDLVIPLSRAAIAVGAHGIIVEVH PEPEKALSDGKQSLDFELFKELVQEMKKLADALGVKVN >1017 bp ATGATAGTCGTTTTGAAACCCGGTTCCACAGAAGAAGATATAAGGAAGGTGGTGAAGTTG GCCGAGAGTTACAACTTGAAGTGTCACATTTCCAAAGGTCAGGAAAGAACGGTTATTGGG ATCATCGGGGACGACAGGTACGTGGTGGCGGACAAGTTCGAGTCGCTGGATTGCGTGGAA AGCGTTGTGAGGGTGCTCAAACCTTACAAACTCGTTTCTCGTGAGTTCCATCCGGAGGAC ACGGTGATCGACCTCGGAGATGTGAAGATAGGAAACGGCTACTTCACCATCATAGCGGGA CCGTGCTCAGTTGAAGGCAGGGAAATGCTCATGGAAACCGCACACTTTTTAAGCGAACTC GGTGTTAAAGTTTTGAGGGGAGGGGCCTACAAGCCTCGAACATCTCCTTACTCTTTCCAA GGACTCGGAGAAAAGGGGCTGGAATACCTGAGAGAGGCTGCCGACAAGTACGGTATGTAC GTGGTGACGGAGGCTCTCGGAGAAGACGATCTTCCAAAAGTGGCCGAGTACGCTGATATC ATTCAGATAGGAGCGAGAAACGCTCAGAACTTCAGATTGCTCTCTAAAGCGGGAAGCTAC AACAAACCCGTTCTTCTGAAAAGGGGTTTCATGAACACCATCGAAGAGTTCCTTCTCTCC GCTGAATACATTGCAAACTCTGGAAACACGAAGATCATACTGTGTGAAAGGGGAATCAGA ACGTTCGAAAAGGCCACGAGGAACACACTCGATATATCCGCTGTTCCTATAATCAGAAAG GAATCCCATCTTCCCATTCTGGTGGATCCGAGCCACTCTGGGGGAAGAAGAGACCTCGTT ATTCCACTCTCCCGGGCCGCTATAGCGGTTGGAGCTCATGGAATCATTGTGGAGGTTCAT CCGGAGCCGGAGAAGGCACTTTCGGATGGAAAACAGAGTCTTGACTTCGAGCTCTTCAAG GAACTGGTTCAGGAAATGAAGAAACTCGCTGATGCCCTGGGGGTGAAGGTGAATTGA PF00793 DAHP_synth_1 function carbon-carbon lyase activity function aldehyde-lyase activity function catalytic activity function lyase activity process amino acid metabolism process amino acid and derivative metabolism process biosynthesis process amino acid biosynthesis process physiological process process aromatic amino acid family biosynthesis process metabolism process cellular metabolism BE0003655 Solute carrier organic anion transporter family member 2A1 Human inhibitor # Chan BS, Endo S, Kanai N, Schuster VL: Identification of lactate as a driving force for prostanoid transport by prostaglandin transporter PGT. Am J Physiol Renal Physiol. 2002 Jun;282(6):F1097-102. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11997326 unknown Solute carrier organic anion transporter family member 2A1 Involved in lipid transporter activity May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A SLCO2A1 3q21 Membrane 27-47 71-91 101-121 172-192 210-230 258-278 328-348 366-386 400-420 511-531 551-571 606-626 8.95 70043.3 Human HUGO Gene Nomenclature Committee (HGNC) GNC:10955 GeneCards SLCO2A1 GenBank Gene Database U70867 GenBank Protein Database 1617590 UniProtKB Q92959 UniProt Accession SO2A1_HUMAN PGT Prostaglandin transporter Solute carrier family 21 member 2 >Solute carrier organic anion transporter family member 2A1 MGLLPKLGASQGSDTSTSRAGRCARSVFGNIKVFVLCQGLLQLCQLLYSAYFKSSLTTIE KRFGLSSSSSGLISSLNEISNAILIIFVSYFGSRVHRPRLIGIGGLFLAAGAFILTLPHF LSEPYQYTLASTGNNSRLQAELCQKHWQDLPPSKCHSTTQNPQKETSSMWGLMVVAQLLA GIGTVPIQPFGISYVDDFSEPSNSPLYISILFAISVFGPAFGYLLGSVMLQIFVDYGRVN TAAVNLVPGDPRWIGAWWLGLLISSALLVLTSFPFFFFPRAMPIGAKRAPATADEARKLE EAKSRGSLVDFIKRFPCIFLRLLMNSLFVLVVLAQCTFSSVIAGLSTFLNKFLEKQYGTS AAYANFLIGAVNLPAAALGMLFGGILMKRFVFSLQAIPRIATTIITISMILCVPLFFMGC STPTVAEVYPPSTSSSIHPQSPACRRDCSCPDSIFHPVCGDNGIEYLSPCHAGCSNINMS SATSKQLIYLNCSCVTGGSASAKTGSCPVPCAHFLLPAIFLISFVSLIACISHNPLYMMV LRVVNQEEKSFAIGVQFLLMRLLAWLPSPALYGLTIDHSCIRWNSLCLGRRGACAYYDND ALRDRYLGLQMGYKALGMLLLCFISWRVKKNKEYNVQKAAGLI >1932 bp ATGGGGCTCCTGCCCAAGCTCGGCGTGTCCCAGGGCAGCGACACCTCTACTAGCCGAGCC GGCCGCTGTGCCCGCTCGGTCTTCGGCAACATTAAGGTGTTTGTGCTCTGCCAAGGCCTC CTGCAGCTCTGCCAACTCCTGTACAGCGCCTACTTCAAGAGCAGCCTCACCACCATTGAG AAGCGCTTTGGGCTCTCCAGTTCTTCATCGGGTCTCATTTCCAGCTTGAATGAGATCAGC AATGCCATCCTCATCATCTTTGTCAGCTACTTTGGCAGCCGGGTGCACCGTCCACGTCTG ATTGGCATCGGAGGTCTCTTCCTGGCTGCAGGTGCCTTCATCCTCACCCTCCCACACTTC CTCTCCGAGCCCTACCAGTACACCTTGGCCAGCACTGGGAACAACAGCCGCTTGCAGGCC GAGCTCTGCCAGAAGCATTGGCAGGACCTGCCTCCCAGTAAGTGCCACAGCACCACCCAG AACCCCCAGAAGGAGACCAGCAGCATGTGGGGCCTGATGGTGGTTGCCCAGCTGCTGGCT GGCATCGGGACAGTGCCTATTCAGCCATTTGGGATCTCCTATGTGGATGACTTCTCAGAG CCCAGCAACTCGCCCCTGTACATCTCCATCTTATTTGCCATCTCTGTATTTGGACCGGCT TTCGGGTACCTGCTGGGCTCTATCATGCTGCAGATCTTTGTGGACTATGGCAGGGTCAAC ACAGCTGCAGTTAACTTGGTCCCGGGTGACCCCCGATGGATTGGAGCCTGGTGGCTAGGC CTGCTCATTTCTTCAGCTTTATTGGTTCTCACCTCTTTCCCCTTTTTTTTCTTCCCTCGA GCAATGCCCATAGGAGCAAAGAGGGCTCCTGCCACAGCAGATGAAGCAAGGAAGTTGGAG GAGGCCAAGTCAAGAGGCTCCCTGGTGGATTTCATTAAACGGTTTCCATGCATCTTTCTG AGGCTCCTGATGAACTCACTCTTCGTCCTGGTGGTCCTGGCCCAGTGCACCTTCTCCTCC GTCATTGCTGGCCTCTCCACCTTCCTCAACAAGTTCCTGGAGAAGCAGTATGGCACCTCA GCAGCCTATGCCAACTTCCTCATTGGTGCTGTGAACCTCCCTGCTGCAGCCTTGGGGATG CTGTTTGGAGGAATCCTCATGAAGCGCTTTGTTTTCTCTCTACAAACCATTCCCCGCATA GCTACCACCATCATCACCATCTCCATGATCCTTTGTGTTCCTTTGTTCTTCATGGGATGC TCCACCCCAACTGTGGCCGAAGTCTACCCCCCTAGCACATCAAGTTCTATACATCCGCAG TCTCCTGCCTGCCGCAGGGACTGCTCGTGCCCAGATTCTATCTTCCACCCGGTCTGTGGA GACAATGGAATCGAGTACCTCTCCCCTTGCCATGCCGGCTGCAGCAACATCAACATGAGC TCTGCAACCTCCAAGCAACTGATCTATTTGAACTGCAGCTGTGTGACCGGGGGATCCGCT TCAGCAAAGACAGGATCGTGCCCTGTCCCCTGTGCCCACTTCCTGCTCCCGGCCATCTTC CTCATCTCCTTCGTGTCCCTGATAGCCTGCATCTCCCACAACCCCCTCTACATGATGGTT CTGCGTGTGGTGAACCAGGAGGAAAAGTCATTTGCCATCGGGGTGCAGTTCTTGTTGATG CGCTTGCTGGCCTGGCTGCCATCTCCAGCCCTCTATGGCCTCACCATTGACCACTCCTGC ATCCGGTGGAACTCGCTGTGCTTGGGGAGGCGAGGGGCCTGCGCCTACTATGACAACGAT GCTCTCCGAGACAGGTACCTGGGCCTGCAGATGGGCTACAAGGCGCTGGGCATGCTGCTG CTTTGCTTCATCAGCTGGAGGGTGAAGAAGAACAAGGAGTACAACGTGCAGAAGGCGGCA GGCCTCATCTGA PF07648 Kazal_2 PF03137 OATP component cell component membrane function transporter activity process physiological process process cellular physiological process process transport "
owl:sameAs	drug:Pyruvic acid drug:Biotin drug:L-Glutamine drug:Succinic acid drug:N-Acetyl-D-glucosamine drug:L-Glutamic Acid drug:Glutathione drug:Glucosamine drug:Potassium drug:Zinc drug:Fumarate drug:2-Phosphoglyceric Acid drug:Phosphoenolpyruvate drug:1,2-Propanediol drug:Glyceraldehyde-3-Phosphate drug:Cytidine-5'-Triphosphate drug:D-Lactic Acid drug:Acetic acid drug:Uridine-5'-Diphosphate drug:Citric Acid drug:1,3-Dihydroxyacetonephosphate drug:Malonyl-Coenzyme A drug:EXPT02550

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines2/drugbank_small.nt

The resource appears as object in 22 triples

Context graph